X CHIOME
LIVE

Serial Number

79169641

Owner

Chiome Bioscience Inc.

Attorney

Jeffrey H. Handelsman

Filing Date

Apr 28, 2015

Add to watchlist:

No watchlists yet
View on USPTO

X CHIOME Trademark

Serial Number: 79169641 • Registration: 5126156

X CHIOME is a trademark filed by Chiome Bioscience Inc. on April 28, 2015. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Chiome Bioscience Inc. (3 trademarks)

3-12-1 Honmachi
Tokyo 151-0071 , JP

Entity Type: 03

Trademark Details

Filing Date

April 28, 2015

Registration Date

January 24, 2017

Published for Opposition

November 8, 2016

Goods & Services

Monoclonal antibodies for medical [ or veterinary ] purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; peptides and proteins for medical [ or veterinary ] purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; [ biological and chemical preparations and reagents for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; ] medicines for human purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders [ ; medicines for dental purposes, namely, for infectious diseases, neurological diseases or inflammatory diseases; medicines for veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicinal preparations, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; living cells for manufacturing monoclonal antibodies used for medical purposes; cell lines for manufacturing monoclonal antibodies used for medical purposes; living cells for manufacturing monoclonal antibodies used for veterinary purposes; cell lines for manufacturing monoclonal antibodies used for veterinary purposes; biological tissue cultures for medical purposes, namely, for cultivating living cells or cell lines used for manufacturing monoclonal antibodies; dietary supplements for humans; nutritional supplements; dietary supplements for animals; dietetic foods, namely, protein adapted for medical purposes; dietetic beverages, namely, protein-based ready to drink beverages adapted for medical purposes; food for babies; powdered milk for babies; lacteal flour for babies; surgical implants comprised of living tissues; biological implants, namely, a vital processed human or animal connective tissue; disinfectants for hygiene purposes; sanitary sterilising preparations; biocides; preparations for destroying vermin ]

Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; [ design and development of medical technology; research and development in the field of biotechnology; ] pharmaceutical research and development [ ; conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; technical project studies in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; research and development of new products for others; design and development of computer software for use with medical technology; software design and development; providing temporary use of non-downloadable business software; rental of computer software; cloud computing featuring software used for development of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products ]

Filing History

COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Jan 24, 2026 REM4
INTERNATIONAL REGISTRATION RENEWED
Oct 9, 2025 RNWL
NEW REPRESENTATIVE AT IB RECEIVED
Apr 18, 2025 NREP
PARTIAL INVALIDATION PROCESSED BY THE IB
Nov 12, 2023 INNP
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Oct 11, 2023 INPS
INVALIDATION PROCESSED
Oct 11, 2023 INPC
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Oct 6, 2023 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Feb 6, 2023 NA71
REGISTERED-SEC.71 ACCEPTED
Feb 6, 2023 71AG
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Feb 3, 2023 APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jan 29, 2023 APRE
TEAS SECTION 71 RECEIVED
Jan 19, 2023 ES71
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jan 24, 2022 REM3
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Aug 4, 2017 OPNX
FINAL DECISION TRANSACTION PROCESSED BY IB
May 12, 2017 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 25, 2017 FICS
FINAL DISPOSITION PROCESSED
Apr 25, 2017 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 24, 2017 FICR
REGISTERED-PRINCIPAL REGISTER
Jan 24, 2017 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 6, 2017 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 4, 2017 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jan 4, 2017 OPNR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 8, 2016 NPUB
PUBLISHED FOR OPPOSITION
Nov 8, 2016 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 19, 2016 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Oct 19, 2016 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 19, 2016 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Oct 3, 2016 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 24, 2016 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 20, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 19, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 19, 2016 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 17, 2016 GNRN
NON-FINAL ACTION E-MAILED
Mar 17, 2016 GNRT
NON-FINAL ACTION WRITTEN
Mar 17, 2016 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 25, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 25, 2016 CRFA
ASSIGNED TO LIE
Feb 19, 2016 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 15, 2016 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 15, 2016 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 15, 2016 REAP
REFUSAL PROCESSED BY IB
Sep 4, 2015 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 14, 2015 RFCS
REFUSAL PROCESSED BY MPU
Aug 14, 2015 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 14, 2015 RFCR
NON-FINAL ACTION WRITTEN
Aug 13, 2015 CNRT
APPLICATION FILING RECEIPT MAILED
Aug 11, 2015 MAFR
ASSIGNED TO EXAMINER
Aug 8, 2015 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 6, 2015 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 30, 2015 REPR